A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

NCT03523858 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

927

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Multiple Sclerosis (PMS)

Interventions

DRUG: Ocrelizumab

Sponsor

Hoffmann-La Roche